HYDRIX LIMITED ersonal use only
Capital Raising Presentation
February 2022
onlyStrategic focus on cardiovascular technologies
useersonal2
Hydrix Medical
Sales of diagnostic, monitoring & interventional cardiovascular products
2025 product revenue objective $50m
Hydrix Services
Design and engineering services transforming client needs into commercial products
Client revenues:
1H FY21 | $3.65m |
FY21 | $7.5m |
1H FY22 | $5.15m |
Hydrix Ventures
Investing in early-stage high potential medical device clients
Cash invested ~$2m - potential 10x uplift
Executive Summary
Company Overview
onlyFocus On Technology To Improve Management of Cardiovascular Disease
Significant News flow / | ||
Inflection Points in CY22 | ||
use | ||
ersonal | Capital Raising & | |
Balance Sheet | ||
Attaching Option | ||
- Diversified global medtech company - 20-year history in medtech product development, Melbourne based, global customers
- Three complementary business segments provide significant operating leverage
- Core strategic focus on technologies that manage cardiovascular disease
- Cardiovascular disease afflicts 14% of the global population, is the leading cause of death, and is predicted to result in US$70B of spending on devices by 2027
- HYD has exclusive rights to distribute TWO disruptive cardiac products that aim to solve unmet market needs
- E.G. The Guardian an 'implantable heart attack alert device,' is at the forefront of real-time emergency Cardiac Event telemedicine. AngelMed received FDA approval in June 2021 and has commenced sales in the USA
- Targeting to bring three or more cardiovascular disease devices to market producing +$50m revenues p.a. in 2025
- The Services business has a healthy pipeline, YTD revenue growth is up +40% improving the bottom line, increasing percentage coming from outside Australia
- Expect to begin receiving AngelMed regulatory approvals throughout SE Asia and to commence commercial sales/implants
- All portfolio venture companies are nearing significant inflection points, valuation outlook suggest returns in the next few years greater than our current market capitalisation
- ~A$2..5m Placement (with the ability to accept oversubscriptions up to $4m) at A$0.10 per share to professional and sophisticated investors
- Offer Price of A$0.10 represents a discount of 20% to the Last Close Price and 25.2% to the 30 day VWAP
- Funds raised to be used for:
- Market development and expansion of cardiac devices portfolio
- Expand global business development and marketing of product design and engineering services
- Venture investments in high potential early stage medtech device clients
- Group working capital in support of strategic objectives
- Fees and costs associated with the Placement and EGM
- New shares issued under the Placement will rank parri passu with existing ordinary shares in Hydrix
- Participants in the Placement will be entitled to receive 1 free attaching option for every 1 share subscribed for.
- Each attaching option will have an exercise price of A$0.18 and an expiry date of 31 March 2024.
- Hydrix intends to apply for quotation of the attaching options.
- The attaching options will be offered under a prospectus to be issued by Hydrix. The issue of the options is also subject to shareholder approval under ASX Listing Rule 7.1. Hydrix intends to hold a general meeting in March / April 2022 to seek this approval.
Hydrix Group: H1 FY22 Financials & Outlook
Strong YoY client revenue growth, approaching significant medical product commercialisation milestones & venture investment uplifts
Client Services (Only) Revenue Growth ($m)
Key Insights
only$9.0
$8.0 $7.0
$6.0
COVID impact
beginning March $8.2 2020
$7.6 | Revenue |
$6.8 | beginning |
recovery | |
$5.7
H1 FY22 Update
• Client services 1HFY22 revenue grew +40% YoY | |
• Greater proportion of revenue generated from outside Australia | |
• | Received FOUR International Good Design Awards |
• | Submitted regulatory approvals in FIVE jurisdictions for AngelMed |
Guardian |
use$5.0 $4.0
$3.0
$2.0
$1.0
$0.0
$3.9
$5.1
$3.7 $3.7
• Appointed Mr Paul Lewis as Non-Executive Director |
Outlook
• FY22 full year-on-year client services revenue growth | |
• | Uplift in valuations across the Ventures portfolio as inflection milestones |
are achieved | |
• | Cash inflows of up to $2.25m from HYDO $0.12c options, if exercised |
ersonal
FY18H2 | FY19H1 | FY19H2 | FY20H1 | FY20H2 | FY21H1 | FY21H2 | FY22H1 |
(expire 31/7/22) |
onlyOur strategic focus
useersonal5
CVD is the
No 1
Cause of death globally
18million | 85% | $70B+ |
Annual global | CVD deaths | CVD device |
CVD related | caused by | market by |
deaths 1 | heart attacks | 2027 2 |
or stroke 1 |
(1) World Health Organisation June 2021
(2) Global Industry Analysts, Inc Reports - April 2021
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Hydrix Limited published this content on 27 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 February 2022 23:21:03 UTC.
